Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
251,80 € ↑6,70 (2,73%)
2026-06-03
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionNorthern Trust Corp
Latest Disclosed Ownership858,120 shares
Latest Disclosed Value $ 283,926,165
Northern Trust Corp reports 0.04% increase in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On May 14, 2026 - Northern Trust Corp filed a 13F-HR form disclosing ownership of 858,120 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $245,164,884 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 857,742 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of 0.04% during the quarter. The current value of the position is $216,074,616 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 858,120 378 0.04 283,926 -16.76 0.0077
2026-02-17 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 857,742 24,591 2.95 341,081 -10.22 0.0435
2025-11-14 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 833,151 1,374 0.17 379,917 40.07 0.0486
2025-08-13 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 831,777 -33,243 -3.84 271,234 16.12 0.0373
2025-05-13 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 865,020 -13,840 -1.57 233,573 12.94 0.0347
2025-02-14 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 878,860 143,941 19.59 206,805 2.32 0.0293
2024-11-13 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 734,919 -45,916 -5.88 202,125 6.53 0.0331
2024-08-14 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 780,835 41,251 5.58 189,743 71.67 0.0320
2024-05-14 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 739,584 -24,936 -3.26 110,531 -24.47 0.0191
2024-02-13 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 764,520 -33,180 -4.16 146,337 3.58 0.0265
2023-11-13 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 797,700 25,230 3.27 141,273 -3.71 0.0274
2023-08-11 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 772,470 10,886 1.43 146,723 -3.83 0.0282
2023-05-15 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 761,584 12,045 1.61 152,561 -14.35 0.0302
2023-02-13 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 749,539 15,547 2.12 178,128 21.24 0.0374
2022-11-14 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 733,992 -2,945 -0.40 146,916 36.69 0.0336
2022-08-12 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 736,937 -26,403 -3.46 107,482 -13.77 0.0230
2022-05-13 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 763,340 -6,073 -0.79 124,646 -4.47 0.0219
2022-02-08 2021-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 769,413 -9,708 -1.25 130,476 -11.30 0.0214
2021-11-15 2021-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 779,121 70,615 9.97 147,106 22.48 0.0260
2021-08-13 2021-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 708,506 -41,706 -5.56 120,106 13.39 0.0212
2021-05-12 2021-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 750,212 7,442 1.00 105,922 9.72 0.0197
2021-02-11 2020-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 742,770 -9,628 -1.28 96,537 -11.88 0.0188
2020-11-16 2020-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 752,398 -22,641 -2.92 109,549 -4.57 0.0240
2020-08-14 2020-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 775,039 78,943 11.34 114,791 51.50 0.0272
2020-05-14 2020-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 696,096 29,075 4.36 75,770 -1.37 0.0218
2020-02-14 2019-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 667,021 483 0.07 76,821 43.32 0.0172
2019-11-13 2019-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 666,538 96,655 16.96 53,602 29.62 0.0128
2019-08-13 2019-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 569,883 11,578 2.07 41,352 -20.74 0.0098
2019-05-13 2019-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 558,305 26,657 5.01 52,175 34.60 0.0129
2019-02-12 2018-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 531,648 37,136 7.51 38,763 -10.43 0.0109
2018-11-14 2018-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 494,512 1,744 0.35 43,279 -10.83 0.0106
2018-09-18 2018-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 492,768 20,992 4.45 48,533 -13.63 0.0123
2018-08-14 2018-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 499,048 27,272 49,151
2018-05-09 2018-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 471,776 -2,833 -0.60 56,189 -6.82 0.0146
2018-02-14 2017-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 474,609 97,881 25.98 60,299 36.23 0.0153
2017-11-13 2017-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 376,728 -292 -0.08 44,262 47.19 0.0115
2017-08-11 2017-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 377,020 17,862 4.97 30,072 63.37 0.0084
2017-05-12 2017-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 359,158 13,199 3.82 18,407 42.12 0.0053
2017-02-13 2016-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 345,959 -26,343 -7.08 12,952 -48.67 0.0040
2016-11-09 2016-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 372,302 7,927 2.18 25,234 24.81 0.0079
2016-08-12 2016-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 364,375 12,927 3.68 20,218 -9.01 0.0066
2016-08-19 2016-03-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 351,448 11,904 3.51 22,221 -30.48 0.0074
2016-05-13 2016-03-31 13F Alnylam Pharmaceutic COMM 02043Q107 351,448 22,060
2016-02-12 2015-12-31 13F Alnylam Pharmaceutic COMM 02043Q107 339,544 -66,757 -16.43 31,965 -2.10 0.0106
2015-11-12 2015-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 406,301 10,698 2.70 32,650 -31.15 0.0109
2015-08-13 2015-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 395,603 73,763 22.92 47,421 41.11 0.0321
2015-08-13 2015-06-30 13F Alnylam Pharmaceutic COMM 002043Q10 29,630 -292,210 3,552 0.0024
2015-05-14 2015-03-31 13F Alnylam Pharmaceutic COMM 02043Q107 321,840 45,575 16.50 33,606 25.41 0.0101
2015-02-12 2014-12-31 13F Alnylam Pharmaceutic COM 02043Q107 276,265 -88 -0.03 26,797 24.15 0.0081
2014-11-13 2014-09-30 13F Alnylam Pharmaceutic COMM 02043Q107 276,353 -387,344 -58.36 21,584 -48.52 0.0068
2014-08-14 2014-06-30 13F ALNYLAM PHARMACEUTICALS com 02043Q107 663,697 -103,447 -13.48 41,926 -18.60 0.0131
2014-05-14 2014-03-31 13F ALNYLAM PHARMACEUTICALS COMM 02043Q107 767,144 -53,641 -6.54 51,506 -2.41 0.0162
2014-02-21 2013-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 820,785 15,307 1.90 52,776 2.36 0.0169
2014-02-12 2013-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 820,785 52,776
2013-11-13 2013-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 805,478 16,023 2.03 51,558 110.68 0.0182
2013-08-09 2013-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 789,455 789,455 24,472 0.0089
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.